Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 908-914

  Mahmoudi, Javad ^a   Nayebi, Alireza Mohajjel ^b,c   Samini, Morteza ^a   Reyhani Rad, Siamak ^d   Babapour, Vahab ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Buspirone; Catalepsy; L DOPA; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; BUSPIRONE; CARBIDOPA; LEVODOPA; OXIDOPAMINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; MALE; NONHUMAN; PARKINSON DISEASE; RAT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80053373365     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70606-5     Document Type: Article

References (24)

1. 1A receptor agonist 8-OH-DAPT in a rat model of levodopa-induced motor complication. Brain Res, 2007, 1127, 177-184.
2. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN: Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord, 2005, 20, 932-936. (Pubitemid 41419506)
3. Carlsson T, Carta M, Winkler C, Björklund A, Kirik D: Serotonin neuron transplants exacerbate L-DOPA indued dyskinesias in a rat model of Parkinson's disease. J Neurosci, 2007, 27, 8011-8022. (Pubitemid 47173327)
4. Carta M, Carlsson T, Kirik D, Björklund A: Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 2007, 130, 1819-1833. (Pubitemid 47343795)
5. Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A: Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord, 2008, 14, S154-S158.
6. Carta M, Carlsson T, Muńoz A, Kirik D, Björklund A: Serotonin-dopamine interaction in induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res, 2008, 172, 465-478.
7. Cenci MA, Lundblad M: Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem, 2006, 99, 381-392. (Pubitemid 44477196)
8. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G: Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res, 2008, 172, 423-463.
9. 1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian. Neuropharmacology, 2008, 55, 1321-1328.
10. 1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl), 2008, 199, 99-108.
11. 1A agonist buspirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves. L-DOPA efficacy. Pharmacol Biochem Behav, 2007, 87, 306-314.
12. Kannari K, Shen H, Arai A, Tomiyama M, Baba M: re-uptake of L-DOPA-derived extra cellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett, 2006, 402, 62-65. (Pubitemid 43766440)
13. Maeda T, Kannari K, Huo S, Arai A, Tomiyama M, Matsunaga M, Suda T: Increase of the striatal serotonergic fibers after nigrostriatal dopaminergic denervation in adult rats. Int Congr Ser, 2003, 1251, 211-215.
14. 1A agonist, ameliorates movement disorder via non dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res, 2006, 1112, 126-133.
15. Meissner W, Hill MP, Tison F, Gross C E, Bezard E: Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci, 2004, 25, 249-253. (Pubitemid 38553826)
16. 1A receptors. DARU, 2010, 18, 41-45.
17. 1B receptor the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.
18. 1A receptor agonists in alleviating motor symptoms of Parkinson's disease. Afr J Pharm Pharmacol, 2010, 4, 4289-4290.
19. 1A receptors in rats. Pharmacol Rep, 2010, 62, 258-264.
20. Nutt JG, Obeso JA, Stocchi F: Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci, 2000, 23, 109-115.
21. Paxinos G, Watson C: The rat brain in stereotaxic coordinates. Academic Press, Sydney, 1982.
22. Soghomonian JJ: L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. Eur J Neurosci, 2006, 24, 2395-2403.
23. 1A receptor agonist prevents behavioral sensitization to L-DOPA in rodent model of Parkinson's disease. Neurosci Res, 2005, 52, 185-194.
24. Yacoubian TA, Standaert DG: Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta, 2009, 1792, 676-687.